Press Releases

Date Title and Summary Additional Formats
Toggle Summary Omnicell Reports Fiscal Year and Fourth Quarter 2020 Results
Record 2020 Total Product Bookings of $1+ billion Full Year 2020 Revenues of $892.2 million Ended Year with 145 Long-Term, Sole-Source Agreements with the Top 300 U.S. Health Systems Entered 2021 with Record Product Backlog of $924 million MOUNTAIN VIEW, Calif. --(BUSINESS WIRE)--Feb....
View HTML
Toggle Summary Omnicell Announces Preliminary Fiscal Year 2020 Financial Results
Company Expects to Exceed Previously Announced Guidance Across All Key Metrics; Provides Full Year 2021 Guidance and Updates Long-Term Targets 2020 Total Product Bookings Expected to be Approximately $1.00 Billion and 2020 Revenues Expected to be $890 Million-$892 Million   Increased Full Year 2021...
View HTML
Toggle Summary Omnicell to Present at the J.P. Morgan 39th Annual Healthcare Conference
MOUNTAIN VIEW, Calif. --(BUSINESS WIRE)--Dec. 15, 2020-- Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced its participation in the following upcoming investor conferences: Randall Lipps ,...
View HTML
Toggle Summary Omnicell to Present at Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. --(BUSINESS WIRE)--Nov. 6, 2020-- Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced its participation in the following upcoming investor conferences: Peter Kuipers , Omnicell...
View HTML
Toggle Summary Omnicell Reports Third Quarter 2020 Results
GAAP and non-GAAP revenues of $213.7 million GAAP net income per diluted share of $0.20 Non-GAAP net income per diluted share of $0.60 MOUNTAIN VIEW, Calif. --(BUSINESS WIRE)--Oct. 27, 2020-- Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for...
View HTML
Toggle Summary Omnicell Completes Acquisition of Pharmaceutical Strategy Group’s Leading 340B Software-Enabled Service Business
Expands pharmacy inventory management capabilities for efficient, compliant management of 340B programs Accelerates Omnicell’s strategic transformation to support the vision of the fully Autonomous Pharmacy , building on the recent launch of Omnicell One Expected to be immediately accretive to...
View HTML
Toggle Summary Omnicell to Release Third Quarter 2020 Earnings Results on October 27, 2020
MOUNTAIN VIEW, Calif. --(BUSINESS WIRE)--Sep. 29, 2020-- Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will hold a conference call on Tuesday, October 27, 2020 , to discuss the Company’s Third Quarter...
View HTML
Toggle Summary Omnicell, Inc. Prices $500 Million 0.25% Convertible Senior Notes Offering (up 37.5% Conversion Premium)
MOUNTAIN VIEW, Calif. --(BUSINESS WIRE)--Sep. 23, 2020-- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, announced today the pricing of $500 million aggregate principal amount of 0.25% Convertible Senior...
View HTML
Toggle Summary Omnicell Announces Proposed Private Placement of $500 Million of Convertible Senior Notes
MOUNTAIN VIEW, Calif. --(BUSINESS WIRE)--Sep. 22, 2020-- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, today announced that it intends to offer, subject to market conditions and other factors, $500.0...
View HTML
Toggle Summary Omnicell to Present at Upcoming Investor Conferences
MOUNTAIN VIEW, Calif. --(BUSINESS WIRE)--Sep. 1, 2020-- Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will present at the following upcoming investor conferences: 2020 Wells Fargo Virtual Healthcare...
View HTML